Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -0.87% | +0.88% | +12.87% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
May. 14 | Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.87% | 70.27M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio Says Data From Phase 1/2 Trial of Dementia Therapy Exceeded Expectations